Parallel transmit for 7T MRI imaging in epilepsy

Not Applicable

Conditions: Epilepsy
Nervous System Diseases

Registration Number: ISRCTN16452095

Lead Sponsor: Cambridge University Hospitals NHS Foundation Trust

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Ongoing

Sex: All

Target Recruitment: 35

Inclusion Criteria

1. Age >18 years
2. Drug-resistant focal epilepsy (DRFE), defined as focal epilepsy that remains refractory to treatment with anti-epileptic medication, defined as continuing to have seizures despite adequate trials of two medications over 2 years
3. A desire to have curative surgery (i.e. the patient is in an established epilepsy surgery pathway)
4. A decision by the treating epileptologist that finding a new lesion, or better characterising a lesion poorly visualised at 3T MRI, would make a material difference to patient treatment options

Exclusion Criteria

1. Pregnancy
2. The presence of non-MRI-safe metal implants
3. Implanted medical devices not certified as compatible with ultrahigh-field MRI (e.g.cardiac pacemakers)
4. Lack of mental capacity to consent to study involvement
5. Severe claustrophobia

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Whether the parallel transmit 7T MRI scan changes the epilepsy multi-disciplinary team's management plan: the MDT management plan is recorded before and after review of 7T, and a decision is made on whether it has changed.

Secondary Outcome Measures

Name	Time	Method
1. Epilepsy surgical outcomes in terms of seizure freedom and quality of life measures, assessed longitudinally after surgery using Engel and ILAE outcome scales and the Quality of Life in Epilepsy Inventory<br>2. Correlation between 7T MRI and stereotactic EEG and neuropathology findings<br>